Today, at the 60th Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, QIAGEN announced the launch of two novel products to deliver actionable insights on a wide range of blood cancers: a new workflow for the QCI Interpret bioinformatics solution for hematological malignancies, and the new QIAact Myeloid DNA UMI Panel for use in myeloid neoplasm research as a Sample to Insight workflow on QIAGEN's GeneReader NGS System.
Meet and talk with our experts at ASH 18, booth #1557!
Featured Products and Solutions
Stop by booth #1557 at ASH to explore our complete Sample to Insight solution for interrogating 25 genes for variants with known significance to clonal myeloid malignancies.
Coupled with QIAGEN Clinical Insight (QCI) Analyze and Interpret, QIAGEN’s secondary and tertiary NGS analysis platform that provides seamless variant detection, interpretation and reporting based on actionability tiers from the 2017 AMP/ASCO/CAP guidelines, the streamlined solution enables sub-classification and prognostic assessment of hematological malignancies, including leukemia, Non-Hodgkin lymphoma, Hodgkin lymphoma and multiple myeloma.
QCI Interpret for myeloid malignancies offers a specialized workflow that guides prognostication and treatment decisions. With features that incorporate cytogenetic information, World Health Organization (WHO) somatic frequencies, and variant-level prognostic evidence from the QIAGEN Knowledge Base, QCI Interpret helps you assess actionability through multiple levels of information.
Meet and talk with our experts at ASH 18, booth #1557!
Featured Products and Solutions
Check out our Sample to Insight oncohematology solutions here.
See you in San Diego!
Your QIAGEN team
